Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal metastases: analysis of short-term outcomes
| Autor: | Miriam Attalla El Halabieh, Carlo Abatini, Stefano Rotolo, Francesco Santullo, Andrea Di Giorgio, Fabio Pacelli, Claudio Lodoli |
|---|---|
| Přispěvatelé: | Rotolo S., Di Giorgio A., Santullo F., Attalla El Halabieh M., Lodoli C., Abatini C., Pacelli F. |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Peritoneal metastasis Colorectal cancer Mitomycin Settore MED/18 - CHIRURGIA GENERALE Hyperthermic Intraperitoneal Chemotherapy 030230 surgery 03 medical and health sciences 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Hyperthermia Adverse effect Survival rate Peritoneal Neoplasms Retrospective Studies Carcinomatosis HIPEC business.industry Induced Mitomycin C Common Terminology Criteria for Adverse Events Cytoreduction Surgical Procedures Hyperthermia Induced Carbon Dioxide Prognosis medicine.disease Combined Modality Therapy HIPEC-CO Surgery Survival Rate 030220 oncology & carcinogenesis Hyperthermic intraperitoneal chemotherapy Colorectal Neoplasms business Cytoreductive surgery |
| Zdroj: | Updates in Surgery. 73:1443-1448 |
| ISSN: | 2038-3312 2038-131X |
| Popis: | Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis (PM) performed at our center. The main endpoints were morbidity, mortality, the temperature of perfusate during HIPEC and metabolic changes throughout the procedure. Morbidity was assessed by analysis of postoperative adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0). Continuous variables of Arterial Blood Gas (ABG) analysis at three time-points were compared by the Student t test. There were no postoperative deaths. The overall grade 3–4 CTCAE complications rate at 30days was 38.4%, with ten severe adverse events occurring to six (23.0%) patients. The temperature within HIPEC perfusion maintained between 41 and 42°C in all cases and we experienced no HIPEC-related intraoperative complications. We observed a significant difference between all baseline and pre-HIPEC ABG parameters evaluated but no statistically significant differences between pre- and post-HIPEC ABG outcomes. This study shows that mitomycin C HIPEC-CO2 is feasible and has a safety profile comparable to that of other HIPEC techniques reported in the literature. Further research is needed to validate prospectively the safety and efficacy of this technique. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink